These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 28089149)

  • 21. Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS.
    Hess CN; Schulte PJ; Newby LK; Steg PG; Dalby AJ; Schweiger MJ; Lewis BS; Armstrong PW; Califf RM; van de Werf F; Harrington RA
    Eur Heart J Acute Cardiovasc Care; 2013 Sep; 2(3):246-55. PubMed ID: 24222836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Additive prognostic value of NT-proBNP over TIMI risk score in intermediate-risk patients with acute coronary syndrome.
    Eren NK; Ertaş F; Yüksek U; Cakir C; Nazli C; Köseoğlu M; Ergene O
    Turk Kardiyol Dern Ars; 2009 Jan; 37(1):1-8. PubMed ID: 19225247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NT-proANP and NT-proBNP circulating levels as predictors of cardiovascular outcome following coronary stent implantation.
    Niccoli G; Conte M; Marchitti S; Montone RA; Fracassi F; Grippo R; Roberto M; Burzotta F; Trani C; Leone AM; Bianchi F; Di Castro S; Volpe M; Crea F; Rubattu S
    Cardiovasc Revasc Med; 2016; 17(3):162-8. PubMed ID: 26987266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2-Hour Infusion in High-Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention.
    Marian MJ; Alli O; Al Solaiman F; Brott BC; Sasse M; Leesar T; Prabhu SD; Leesar MA
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28611098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. N-terminal B-type natriuretic peptide assessment provides incremental prognostic information in patients with acute coronary syndromes and normal troponin T values upon admission.
    Weber M; Bazzino O; Navarro Estrada JL; Fuselli JJ; Botto F; Perez de Arenaza D; Möllmann H; Nef HN; Elsässer A; Hamm CW
    J Am Coll Cardiol; 2008 Mar; 51(12):1188-95. PubMed ID: 18355657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The value of N-terminal proB-type natriuretic peptide for early identification of myocardial infarction in patients with high-risk non-ST-elevation acute coronary syndromes.
    Riezebos RK; Laarman GJ; Tijssen JGP; Verheugt FWA
    Clin Chem Lab Med; 2011 Aug; 49(8):1359-1365. PubMed ID: 21692686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.
    Wolsk E; Claggett B; Pfeffer MA; Diaz R; Dickstein K; Gerstein HC; Lawson FC; Lewis EF; Maggioni AP; McMurray JJV; Probstfield JL; Riddle MC; Solomon SD; Tardif JC; Køber L
    J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28554908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of abciximab versus eptifibatide during percutaneous coronary intervention in ST-segment elevation myocardial infarction (from the HORIZONS-AMI trial).
    Singh HS; Dangas GD; Guagliumi G; Yu J; Witzenbichler B; Kornowski R; Grines C; Gersh B; Dudek D; Mehran R; Stone GW
    Am J Cardiol; 2012 Oct; 110(7):940-7. PubMed ID: 22748356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.
    Zeymer U; Margenet A; Haude M; Bode C; Lablanche JM; Heuer H; Schröder R; Kropff S; Bourkaib R; Banik N; Zahn R; Teiger E
    J Am Coll Cardiol; 2010 Aug; 56(6):463-9. PubMed ID: 20670755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Difference in elevation of N-terminal pro-BNP and conventional cardiac markers between patients with ST elevation vs non-ST elevation acute coronary syndrome.
    Ogawa A; Seino Y; Yamashita T; Ogata K; Takano T
    Circ J; 2006 Nov; 70(11):1372-8. PubMed ID: 17062956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial.
    Kaul P; Tanguay JF; Newby LK; Hochman JS; Westerhout CM; Califf RM; Tricoci P; Gibson CM; Giugliano RP; Harrington RA; Van de Werf F; Armstrong PW
    Am Heart J; 2013 Oct; 166(4):723-8. PubMed ID: 24093853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: a substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial.
    Jarai R; Huber K; Bogaerts K; Droogne W; Ezekowitz J; Granger CB; Sinnaeve PR; Ross AM; Zeymer U; Armstrong PW; Van de Werf FJ;
    Am Heart J; 2010 Jan; 159(1):131-40. PubMed ID: 20102879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of early tirofiban administration on N-terminal pro-B-type natriuretic peptide level in patients treated with primary percutaneous coronary intervention.
    Fabris E; Ottervanger JP; Hermanides RS; Ten Berg JM; Sinagra G; Koopmans PC; Giannitsis E; Hamm C; van 't Hof AWJ
    Catheter Cardiovasc Interv; 2019 Apr; 93(5):E293-E297. PubMed ID: 30585388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EuroSCORE II and N-terminal pro-B-type natriuretic peptide for risk evaluation: an observational longitudinal study in patients undergoing coronary artery bypass graft surgery.
    Holm J; Vidlund M; Vanky F; Friberg Ö; Håkanson E; Walther S; Svedjeholm R
    Br J Anaesth; 2014 Jul; 113(1):75-82. PubMed ID: 24727704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [N-terminal pro-brain natriuretic peptide (NT-proBNP) and ischemia modified albumin (IMA) in exercise induced ischemia in patients with stable coronary artery disease].
    Piechota WN; Wierzbowski R; Piechota WT; Bejm J; Gielerak G
    Pol Arch Med Wewn; 2006 Jul; 116(1):640-7. PubMed ID: 17340970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Wallentin L; Lindholm D; Siegbahn A; Wernroth L; Becker RC; Cannon CP; Cornel JH; Himmelmann A; Giannitsis E; Harrington RA; Held C; Husted S; Katus HA; Mahaffey KW; Steg PG; Storey RF; James SK;
    Circulation; 2014 Jan; 129(3):293-303. PubMed ID: 24170388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short- and long-term risk stratification in acute coronary syndromes: the added value of quantitative ST-segment depression and multiple biomarkers.
    Westerhout CM; Fu Y; Lauer MS; James S; Armstrong PW; Al-Hattab E; Califf RM; Simoons ML; Wallentin L; Boersma E;
    J Am Coll Cardiol; 2006 Sep; 48(5):939-47. PubMed ID: 16949483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved risk stratification of patients with acute coronary syndromes using a combination of hsTnT, NT-proBNP and hsCRP with the GRACE score.
    Klingenberg R; Aghlmandi S; Räber L; Gencer B; Nanchen D; Heg D; Carballo S; Rodondi N; Mach F; Windecker S; Jüni P; von Eckardstein A; Matter CM; Lüscher TF
    Eur Heart J Acute Cardiovasc Care; 2018 Mar; 7(2):129-138. PubMed ID: 28029055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study.
    Lindholm D; James SK; Gabrysch K; Storey RF; Himmelmann A; Cannon CP; Mahaffey KW; Steg PG; Held C; Siegbahn A; Wallentin L
    JAMA Cardiol; 2018 Dec; 3(12):1160-1166. PubMed ID: 30427997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP
    Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.